Legitimate scientific research at the University of Iowa on high dose intravenous vitamin C as an adjuvant cancer treatment.
Quoted:
The trial examined the impact of adding high-dose intravenous (IV) vitamin C (ascorbate) to standard chemotherapy treatments for 34 patients with Stage 4 metastatic pancreatic cancer. The results of the phase 2 trial—published in the November 2024 issue of Redox Biology—found that the patients' survival rates doubled from eight months to 16 months, and progression-free survival stretched from three months to six.
"When we started the trial, we thought it would be successful to get to 12 months of survival. Instead, we doubled it," says Joseph Cullen (86MD, 91R), professor of surgery and radiation oncology, and the study's senior author.
Many of the patients in the study didn't just live longer—they also appeared to feel better.
"What's really cool is that if you look at the group who received the vitamin C treatment, they got higher doses of chemotherapy for longer periods,” Cullen says. “They seemed to tolerate the chemotherapy better."
Decades of research at Iowa has shown that vitamin C, when given intravenously, can build up in high levels in the blood, creating unique chemical reactions that make cancer cells more vulnerable to chemotherapy and radiation treatments. Cullen notes that with one of the research team’s phase 1 trials for pancreatic cancer—combining high-dose, IV vitamin C with radiation treatments—three patients are now long-term cancer survivors.
"They've lived nine years since their diagnosis at this point, which is far beyond the typical survival range," Cullen says.
Iowa researchers are now conducting several new trials exploring different vitamin C treatments and their effects on a wide range of cancers.


